Clinical trial
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With…
NCT00027703 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00027703 |
|---|---|
| Title | Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma |
| Official title | A Double Blind, Placebo Controlled Randomized Phase II Trial Of Gemcitabine And Cisplatin With Or Without The VEGF Inhibitor Bevacizumab (NSC #704865) In Patients With Malignant Mesotheloma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Localized Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma |
| Intervention type | Biological, Drug, Other |
| Interventions | gemcitabine hydrochloride, cisplatin, bevacizumab, placebo, laboratory biomarker analysis |
| Enrollment | 106 |
| Start date | Oct 1, 2001 |
| Primary completion | May 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 11, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: